Sunday, 14 April 2024


Soleno Therapeutics executive sells over $91k in stock By

Soleno Therapeutics executive sells over $91k in stock By

Soleno Therapeutics Inc. (NASDAQ:), a company specializing in electromedical and electrotherapeutic apparatus, reported that Senior Vice President of Regulatory Affairs, Patricia C. Hirano, sold a total of $91,693 worth of company stock. The transactions occurred on April 1, 2024, and were made public through a recent filing.

The sales were executed in multiple trades with prices ranging from $40.42 to $42.28. Specifically, Hirano sold 1,330 shares at an average price of $41.1227 and 888 shares at an average price of $41.6671. These sales were part of a plan to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Hirano still owns a significant number of shares, including RSUs which represent a contingent right to receive additional shares of common stock upon vesting.

Investors often monitor insider sales as they may provide insights into an executive’s perspective on the company’s current valuation and future prospects. The disclosure of such sales is a routine part of corporate transparency and is required by securities regulations.

The company’s stock, traded under the ticker SLNO, may experience movements following the announcement of these sales, as market participants digest the news. Soleno Therapeutics Inc. continues to operate in its sector, developing innovative solutions in the medical device field.

InvestingPro Insights

Soleno Therapeutics Inc. (NASDAQ:SLNO) has been navigating a dynamic market, evidenced by the substantial price uptick over the last six months, which has seen a 64.6% increase. This robust performance aligns with a staggering one-year price total return of 1654.62%, demonstrating a significant surge in investor confidence and market valuation for the company.

In terms of financial health, an InvestingPro Tip highlights that Soleno Therapeutics holds more cash than debt on its balance sheet, which could provide a cushion against market volatility and ensure operational resilience. Additionally, analysts predict the company will be profitable this year, a promising outlook that may influence investor sentiment and stock performance in the coming months.

However, the company’s current Price / Book ratio stands at a high 8.61 as of the last twelve months ending Q4 2023. This indicates that the stock is trading at a premium compared to the company’s book value, which could suggest a rich valuation or high investor expectations for future growth.


Click Here to Read the Full Original Article at All News…